N/A N=55 Visual and Electromyography Assessments in Response to Train-of-Four Stimulation of the Ulnar Nerve
Residual Neuromuscular Blockade
Primary: Subjective Evaluation to Neurostimulation — 48.2; 44.8 percentage of evaluations
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
Phase 2 N=79 A Study to Assess the Safety of GRF6021 Infusions in Subjects With Parkinson's Disease and Cognitive Impairment
Parkinson Disease
Primary: Incidence of Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 45; 20; 5; 0 participants
Phase 3 N=309 Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)
Vulvovaginal Atrophy
Primary: Number of Participants With Endometrial Biopsy Results at Final Visit — 3; 10; 7; 166 Participants
N/A N=55 Quantifying Patient-Specific Changes in Neuromuscular Control in Cerebral Palsy
Cerebral Palsy
Primary: Change in Walk Dynamic Motor Control Index 6-months After Orthopaedic Surgery — -2.4 normalized z-score
N/A N=157 i-Scan for the Detection of Helicobacter Pylori
Gastritis
Primary: Successful Diagnosis of Helicobacter Pylori Using Imaging Modality — 28; 125 Participants
Phase 3 N=1,010 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
Sick Sinus Syndrome · Complete Heart Block · Syncope
Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants
Phase 3 N=550 Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia
Vulvovaginal Atrophy
Primary: Change From Baseline in Participant's Self-Assessment of Symptom of Vulvovaginal Atrophy (VVA): Dyspareunia (Pain Associated With Sexual Activity) to Final Assessment…
Phase 2 N=274 An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers
Gastric Cancer · Cancer of the Stomach · Esophagogastric Junction
Primary: BICR-Assessed Objective Response Rate (ORR) in Randomized LAG-3 Positive (>=1 %) Participants — 48.5; 61.2 Percentage of Participants
Phase 2 N=22 Weekly Isotretinoin Therapy Study
Acne Vulgaris
Primary: Number of Participants That Showed Improvement in Their Visible Acne (Efficacy of Once Weekly Isotretinoin) — 18 Participants
N/A N=89 The Effect of Anesthesia on Neurodevelopmental Outcome (NDO)
Anesthesia; Adverse Effect · Congenital Heart Disease · Neurodevelopmental Disorders
Primary: Bayley III — 91; 93; 88; 90 score on a scale
Phase 3 N=3,246 Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBC
Breast Cancer
Primary: Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) During Treatment With Ribociclib + Letrozole in the Core Phase — 3203; 2461; 3091; 2192…
Phase 3 N=13 A Study of Ravulizumab (ALXN1210) in Children and Adolescents With Paroxysmal Nocturnal Hemoglobinuria
Paroxysmal Nocturnal Hemoglobinuria
Primary: Maximum Observed Serum Concentration (Cmax) Of Ravulizumab — 725.40; 884.63; 1161.60; 1612.50 μg/mL
Phase 3 N=576 Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women
Vulvovaginal Atrophy
Primary: Change From Baseline in Participant's Self-Assessment of Severity of Vaginal Dryness to Final Assessment — 2.5; 2.5; -1.2; -1.4 score on a scale
Phase 2 N=161 ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies
Follicular Lymphoma (FL) · CLL · Small Lymphocytic Lymphoma (SLL)
Primary: Number of Participants With Treatment Emergent Adverse Events (AEs) — 160 Number of participants